Jilin Joinature is China's largest producer of polyetheretherketone (PEEK), the high-performance semi-crystalline thermoplastic that replaces metal in demanding automotive, electronics, industrial, energy, medical-implant and aerospace parts. By its own account it was the world's fourth producer to reach 1,000-tonne annual PEEK capacity, after Victrex (UK), Solvay/Syensqo (Belgium) and Evonik (Germany). It was also the second producer globally, after Victrex, to polymerise PEEK in 5,000-litre reactors. In 2025 it sold more than 1,000 tonnes for the first time (1,079.84 t, +11.84%) with a design capacity of 1,000 t/y running at 102% utilisation, and it claims domestic volumes now exceed Victrex's in China. Revenue is small (CNY 309 M in FY2025). Profitability has compressed sharply because of subsidiary build-out and R&D, even as gross margin rose to 44%. The investment case now rests on a CNY 1.2 bn, 10,000 t/y PEEK plus 2,000 t/y monomer integrated complex in Zhangjiagang, Jiangsu. That project would raise capacity elevenfold into a market facing a wave of domestic capacity additions.
---
### Company's own description (FY2024 annual report summary, paraphrased and translated)
The company describes itself as a high-tech enterprise focused on the R&D, production and sale of PEEK. It says more than a decade of in-house development has produced breakthroughs in PEEK synthesis, purification and composite reinforcement. It claims fully domestic, full-process production capability covering five areas: key raw-material selection, process control, equipment design, process optimisation and indicator monitoring. It cites an appraisal organised by the China Synthetic Resin Association concluding that its main product performance indicators reach international advanced level and fill a domestic gap, and that its industrial-scale PEEK technology leads in China.
Its products are resin-form PEEK organised as "two categories, three grades, seven series" with 89 specifications (FY2024). This expanded from 52 specifications in "six series" in earlier descriptions (Morningstar profile).
**Two categories:** pure resin, and composite-reinforced resin (glass fibre or carbon fibre).
**Three melt-flow grades:** 770, 550 and 330, from low to high flow.
**Seven series:** coarse powder (P), fine powder (PF), pellets (G), glass-fibre pellets (GL), carbon-fibre pellets (CA), wear-resistant pellets (FC), and application-customised products. The company also sells a small volume of finished PEEK parts.
### Business model and revenue model
**Revenue model:** almost 100% product sales of PEEK resin and compounds, priced per tonne. There is no material service, subscription or licensing revenue. A small "PEEK products" line (finished parts, partly sourced from fabricators as samples and partly sold by the Shenzhen subsidiary) was under 2% of main-business revenue in 2023–2025 (derived from Inquiry Reply).
**Pricing mechanism:** at the start of each year the company sets guide prices for each grade based on cost, market conditions and strategy. These are not adjusted intra-year absent major raw-material or market shifts. Order prices are negotiated off the guide price by customer type, competitive situation, relationship history, volume and payment terms (Inquiry Reply, Q1). Rebates in kind are used: some customers stocked up in 2025 "to obtain better in-kind rebates".
**Unit economics:** average selling price (ASP) fell from CNY 321,900/t (2023) to CNY 287,000/t (2024) after a deliberate price cut. It was broadly stable in 2025; the derived ASP is about CNY 286,000/t on 1,079.84 t. Gross margin nonetheless rose from 39.48% (2023) to 40.08% (2024) and 44.05% (2025). The driver was cost: the main monomer, 4,4'-difluorobenzophenone (DFBP or "fluoroketone"), makes up roughly 50% of coarse-powder cost, and its purchase price fell 33.53% (2024) and 3.28% (2025). Production-line automation also lowered consumption per tonne (Inquiry Reply).
### Value-chain position
Joinature sits in the polymerisation and compounding stage:
**Upstream (purchased):** DFBP from Zhejiang Zhongxin Fluoride Materials, Xinhan New Materials and Xingfu New Materials, plus hydroquinone, diphenyl sulfone, sodium carbonate, and carbon and glass fibres. About 0.7–0.8 t of DFBP is consumed per tonne of PEEK (Inquiry Reply).
**Midstream (core):** polymerisation, purification and drying into coarse powder; then grinding into fine powder, melt-filtration into pellets, or compounding into GF, CF or wear grades.
**Downstream (customers):** extruders, injection moulders, compression moulders and coaters who make stock shapes, film, wire, monofilament and parts.
**Forward integration under way:** a Shenzhen PEEK application and processing centre (parts), a Shanghai CF/PEEK composite R&D centre, and an extrusion profile line.
**Backward integration planned:** 2,000 t/y of PEEK monomer capacity within the Zhangjiagang project.
### Customer types and end-markets
**Customer types:** stock-shape ("profile", 型材) extruders, which the company says are currently its largest revenue group. Others are injection moulders, compression moulders, coaters, compounders, traders and distributors, and medical-device OEMs.
**Named customers and partners:** BYD; Xi'an Kangtuo Medical; Weigao Orthopaedics; Dabo Medical; Guangzhou Medprin (Inquiry Reply; FY2024 annual report).
**Customer concentration (Inquiry Reply, Q2):** - Top-5 customer share: 43.99% (2023), 36.84% (2024), 33.34% (2025).
- Top-10 customer share: 57.97% (2023), 49.40% (2024), 50.27% (2025).
**End-markets cited by the company:** automotive and transport (including NEV motor enamelled wire and battery seals), electronics and semiconductors (CMP retaining rings, wafer carriers, phone fixtures, speaker diaphragms), industrial machinery and energy (seals, compressor valve plates, bearings), medical implants, aerospace, humanoid robots and the low-altitude economy, and 3D printing (Longbridge profile; FY2024 AR; Inquiry Reply).
### Independent characterisation
Joinature is best understood as a single-polymer, sub-scale specialty-chemicals manufacturer that has won the Chinese industrial-grade PEEK market on cost and availability. It is now trying to move up-mix (medical, semiconductor, aerospace) and up-scale (10 kt) simultaneously.
**Strengths:** a decade-plus of process know-how, a proven 5,000 L reactor process, high utilisation and rising gross margins.
**Weaknesses:** its customer base is still dominated by price-sensitive stock-shape extruders. Its premium-segment penetration (medical-implant revenue was only CNY 5.17 M cumulatively over 2023–2025) is embryonic. Its overseas share is below 1%.
**Profit trend:** reported profitability has collapsed from CNY 54.6 M (2023) to CNY 11.9 M (2025) and a CNY 13.0 M loss in H1 2026, as operating expenses scale ahead of revenue.
**Investment profile:** the business is effectively a capacity-expansion option on Chinese PEEK demand, funded largely by IPO cash and prospective bank debt.